title: Dosing of raltegravir when given with rifampicin.
authors.affiliation: Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa; Department of Medicine, Imperial College, London W2 1PG, UK. Electronic address: graemein@mweb.co.za.
authors.forename: Graeme
authors.initials: G
authors.lastname: Meintjes
authors.affiliation: Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa; Department of Medicine, University of Cape Town, Cape Town 7925, South Africa.
authors.forename: Gary
authors.initials: G
authors.lastname: Maartens
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008297:Male; D011760:Pyrrolidinones / Q000008:administration & dosage*; D000068898:Raltegravir Potassium; D014376:Tuberculosis / Q000188:drug therapy*
chemical_list: D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium